PDS Biotechnology CorpPDSB

PDS Biotechnology filed its latest quarterly report on 23 May 2026, and the numbers read like a biotech that’s still in the lab rather than on the market: the company lost $7.3 million in the three months to 31 March 2026, booked $24.7 million in assets against $20.8 million of liabilities, and counted $21.7 million in cash while burning $4.4 million in operating cash. Diluted earnings per share came in at -$0.13 on a diluted share count of 55.5 million, a tally that hasn’t been trimmed by buybacks, special dividends, or any material revenue line. The balance sheet’s equity footnote clocks in at $3.9 million, a figure that sits between “hand-to-mouth” and “hand-in-the-cookie-jar” depending on how many more cookies the board plans to bake. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1472091/000147209126000044/0001472091-26-000044-index.htm)

PDS describes itself as a clinical-stage immunotherapy company developing Versamune®-based platforms for oncology and Infectimune® for vaccines, with a pipeline anchored on PDS01ADC and Versamune® combinations. The public site and filings drip with the usual biotech cadence-“novel,” “powerful,” “safe,” “versatile”-but the cash flow statement is the only document that tells a story without adjectives. Research and development spend was $3.5 million in the quarter, while capital expenditure remains at zero, a pair of figures that underline the pre-revenue, pre-commercial stage of the business. The 8-K filed on 15 June 2026 confirms a sales agreement with Yorkville Securities giving the broker a 3% commission on any future placement proceeds, a structure that looks less like a distribution deal and more like a desperate attempt to keep the lights on while the clinic churns out data. (source: PDSB SEC EDGAR 8-K (2026-06-15), https://www.sec.gov/Archives/edgar/data/1472091/000114036126025207/ef20076071_8k.htm)

The company’s most visible filing this month is the S-3 registration statement dated 10 July 2026, used to register unspecified securities for future sale-a classic “we may need cash, but we’re not telling you when” document. The accompanying 424B4 prospectus supplement dated 21 July 2026 repeats the Versamune® and Infectimune® scripts without adding a single dollar of revenue guidance, clinical-trial enrollment target, or near-term approval pathway. That’s not a data room; it’s a data waiting room. The DEF 14A filed on 26 June 2026 is the governance mirror: it approves the 2014 equity plan amendments and restatements, a document that exists so the board can promise equity without promising results. The charter, hosted on the company website, is where governance aspirations go to die quietly. (source: S-3 (2026-07-10), https://www.sec.gov/Archives/edgar/data/1472091/000114036126028217/ny20077374x1_s3.htm; 424B4 (2026-07-21), https://www.sec.gov/Archives/edgar/data/1472091/000114036126029135/ny20077374x3_424b4.htm; DEF 14A (2026-06-26), https://www.sec.gov/Archives/edgar/data/1472091/000114036126026564/ny20075675x2_def14a.htm)

Investors chasing the Versamune® story should note the 15 April 2026 press release celebrating “positive interim Phase 2 clinical trial data” for PDS01ADC in a National Cancer Institute-led metastatic colorectal cancer trial. The company and its site furnish a product image and headline copy, but the filing record contains no granular disclosure on sample size, response rate, durability, or comparator arm. Until the SEC or a peer-reviewed journal publishes the protocol and outcomes, the “positive” label remains a marketing assertion rather than a verified clinical result. The SEC EDGAR index for PDS Biotechnology runs to hundreds of documents, yet none of them yet show a product on the market, a payer contract, or a revenue line that isn’t a promise. (source: PDS Biotechnology press release, https://www.pdsbiotech.com/index.php/investors/news-center/press-releases/press-releases1/134-2026-news/1035-pds-biotech-announces-publication-of-positive-pds01adc-inter2026-04-15-055033; SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=1472091)

For context on the company’s market plumbing, the SEC submissions JSON shows a steady drumbeat of registration statements, prospectus supplements, and investor presentations, none of which yet translate into traded volume or price discovery. The absence of buybacks, dividends, or material asset purchases means the stock’s day-to-day moves are driven by sentiment rather than fundamentals-good news if you’re short volatility, bad news if you’re waiting for clinical catalysts to land. The company’s SEC companyfacts JSON confirms the same data points-losses, cash burn, and R&D spend-but adds no surprises. In short, this is a company whose public filings are exhaustive, whose product narrative is polished, and whose balance sheet is thin. (source: SEC submissions JSON, https://data.sec.gov/submissions/CIK0001472091.json; SEC companyfacts JSON, https://data.sec.gov/api/xbrl/companyfacts/CIK0001472091.json)